Edited by Alfred I. Neugut, Anna T. Meadows, and Eliezer Robinson. 484 pp., illustrated. Baltimore, Lippincott Williams & Wilkins, 1999. $110. ISBN 0-683-30124-1.
In this era of modern cancer medicine, there are now 8 millionto 10 million survivors of cancer in the United States, a numberthat increases each year. Although many survivors are "cured"of their cancer, they remain at risk for second neoplasms. Thebest described of the second cancers, acute leukemia, can bea consequence of the DNA-damaging therapies that are the mainstayof most chemotherapy regimens. In other cases, the risk of secondneoplasms is associated not with the effects of treatment but,instead, with a hereditary predisposition to cancer. In bothcircumstances, the study of patients with . . . [Full Text of this Article]
Previous
